Moon Lake Immunotherapeutics MLTX

MLTX Quotes by TradingView
Institutional shares held 58.2 Million
52.2K calls
38K puts
Total value of holdings $2.74B
$2.46M calls
$1.79M puts
Market Cap $1.7B
36,925,600 Shares Out.
Institutional ownership 157.67%
# of Institutions 125

Quarterly Institutional Activity in MLTX

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding MLTX

View all
View all

Latest Institutional Activity in MLTX

Top Purchases

Q4 2024
Rice Hall James & Associates, LLC Shares Held: 111K ($5.11M)
35.7K Shares purchased
47.26% Added
Q4 2024
Congress Asset Management CO Shares Held: 73K ($3.36M)
6.35K Shares purchased
9.53% Added
Q4 2024
Harbor Capital Advisors, Inc. Shares Held: 79.6K ($3.66M)
2.18K Shares purchased
2.81% Added
Q4 2024
Skopos Labs, Inc. Shares Held: 78 ($3.59K)
78 Shares purchased
New Holding
Q4 2024
Geneos Wealth Management Inc. Shares Held: 14 ($644)
14 Shares purchased
New Holding
View All Buyers

Top Sells

Q3 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 505K ($23.2M)
1.32M Shares sold
72.33% Reduced
Q3 2024
Balyasny Asset Management LLC Shares Held: 360K ($16.6M)
224K Shares sold
38.35% Reduced
Q3 2024
Wellington Management Group LLP Shares Held: 192K ($8.83M)
181K Shares sold
48.46% Reduced
Q3 2024
Polar Capital Holdings PLC Shares Held: 500K ($23M)
178K Shares sold
26.27% Reduced
Q3 2024
Ghost Tree Capital, LLC Shares Held: 128K ($5.91M)
172K Shares sold
57.2% Reduced
View All Sellers

About MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MLTX Chart by TradingView
MLTX Fundamental Data by TradingView

Insider Transactions at MLTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Jan 20 2025
Kristian Reich Chief Scientific Officer
SELL
Sale (or disposition) back to the issuer
Direct
111,949 -57.02%
-
Jan 20 2025
Kristian Reich Chief Scientific Officer
BUY
Conversion of derivative security
Direct
111,949 +42.11%
-
Oct 04 2024
Bvf Partners L P Director
SELL
Open market or private sale
Direct
2,000,000 -9.26%
$100,000,000 $50.0 P/Share
Oct 04 2024
Simon Sturge Director
SELL
Open market or private sale
Direct
171,000 -49.86%
$9,063,000 $53.72 P/Share
Feb 29 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
4,740 -0.16%
$260,700 $55.89 P/Share
Feb 28 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
56,065 -1.84%
$3,083,575 $55.0 P/Share
Feb 28 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Direct
28,090 -40.09%
$1,544,950 $55.0 P/Share
Feb 28 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Indirect
31,910 -1.08%
$1,755,050 $55.0 P/Share
Feb 27 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
62,810 -2.02%
$3,454,550 $55.0 P/Share
Feb 27 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Direct
29,431 -29.58%
$1,618,705 $55.0 P/Share
Feb 21 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
1,125 -0.04%
$61,875 $55.27 P/Share
Feb 21 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Direct
569 -0.57%
$31,295 $55.3 P/Share
Feb 21 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Indirect
509 -0.02%
$27,995 $55.31 P/Share
Feb 20 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Direct
10,000 -9.09%
$570,000 $57.43 P/Share
Feb 20 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Indirect
10,000 -0.33%
$570,000 $57.45 P/Share
Feb 20 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
20,000 -0.64%
$1,140,000 $57.44 P/Share
Feb 16 2024
Da Silva Jorge Santos Chief Executive Officer
SELL
Open market or private sale
Direct
20,000 -0.64%
$1,200,000 $60.15 P/Share
Feb 16 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Direct
10,000 -8.33%
$600,000 $60.15 P/Share
Feb 16 2024
Kristian Reich Chief Scientific Officer
SELL
Open market or private sale
Indirect
10,000 -0.33%
$600,000 $60.15 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
112K Shares
From 1 Insiders
Conversion of derivative security 112K shares
Sell / Disposition
2.67M Shares
From 5 Insiders
Open market or private sale 2.56M shares
Sale (or disposition) back to the issuer 112K shares

Track Institutional and Insider Activities on MLTX

Follow MoonLake Immunotherapeutics and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MLTX shares.

Notify only if

Insider Trading

Get notified when an Moon Lake Immunotherapeutics insider buys or sells MLTX shares.

Notify only if

News

Receive news related to MoonLake Immunotherapeutics

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on MLTX